(OMI) Owens & Minor - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6907321029

Stock: Medical, Surgical, Diabetes, Respiratory, Ostomy

Total Rating 7

Risk 35

Buy Signal -0.86

Medical Distribution » Health Care Distributors
Age: 37.1y

Market Cap: 217m
Avg Trading Vol: 2.91M USD

ATR: 9.38%
Peers RS (IBD): 4.29

EPS (Earnings per Share)

EPS CAGR: -59.98%
EPS Trend: -50.9%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: -28.61%
Rev. Trend: -59.5%

Last SUE: -0.01
Qual. Beats: 0

Risk 5d forecast
Volatility	82.8%
Relative Tail Risk	-14.1%

Reward TTM
Sharpe Ratio	-1.00
Alpha	-86.28

Character TTM
Beta	0.783
Beta Downside	1.059

Drawdowns 3y
Max DD	93.17%
CAGR/Max DD	-0.56

Description: OMI Owens & Minor December 26, 2025

Owens & Minor (NYSE: OMI) is a global healthcare solutions provider operating through two segments: Products & Healthcare Services, which supplies branded and proprietary medical-surgical items and offers supplier-management, analytics, and logistics services; and Patient Direct, which delivers in-home care products for diabetes, respiratory therapy, sleep apnea, and other chronic-care needs. The company serves multi-facility health networks, independent hospitals, surgery centers, physician practices, and hospital systems both directly and via third-party distributors. Founded in 1882, OMI is headquartered in Glen Allen, Virginia.

Key recent metrics include FY 2023 revenue of roughly $7.5 billion, with the Patient Direct segment growing at a 12% YoY rate driven by expanding home-based care adoption. The broader health-care distribution sector is being propelled by an aging U.S. population, a shift toward outpatient services, and rising Medicare reimbursement pressures, all of which influence OMI’s inventory-turnover and margin dynamics.

For a deeper, data-rich perspective on OMI’s valuation and risk profile, you may find ValueRay’s independent analysis worth reviewing.

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income: -1.34b TTM > 0 and > 6% of Revenue
FCF/TA: -0.09 > 0.02 and ΔFCF/TA -8.51 > 1.0
NWC/Revenue: -4.98% < 20% (prev 3.93%; Δ -8.91% < -1%)
CFO/TA -0.02 > 3% & CFO -99.0m > Net Income -1.34b
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 0.86 > 1.5 & < 3
Outstanding Shares: last quarter (77.3m) vs 12m ago 0.26% < -2%
Gross Margin: 26.13% > 18% (prev 0.33%; Δ 2580 % > 0.5%)
Asset Turnover: 147.1% > 50% (prev 91.34%; Δ 55.79% > 0%)
Interest Coverage Ratio: -2.09 > 6 (EBITDA TTM -48.8m / Interest Expense TTM 143.0m)

Altman Z'' -2.02

A: -0.08 (Total Current Assets 2.13b - Total Current Liabilities 2.47b) / Total Assets 4.04b
B: -0.25 (Retained Earnings -1.02b / Total Assets 4.04b)
C: -0.07 (EBIT TTM -298.6m / Avg Total Assets 4.56b)
D: -0.20 (Book Value of Equity -898.0m / Total Liabilities 4.47b)
Altman-Z'' Score: -2.02 = D

Beneish M -3.50

DSRI: 0.21 (Receivables 202.7m/661.7m, Revenue 6.71b/4.64b)
GMI: 1.25 (GM 26.13% / 32.69%)
AQI: 0.91 (AQ_t 0.38 / AQ_t-1 0.42)
SGI: 1.45 (Revenue 6.71b / 4.64b)
TATA: -0.31 (NI -1.34b - CFO -99.0m) / TA 4.04b)
Beneish M-Score: -3.50 (Cap -4..+1) = AA

What is the price of OMI shares?

As of February 07, 2026, the stock is trading at USD 2.39 with a total of 664,411 shares traded.
Over the past week, the price has changed by +8.14%, over one month by +25.13%, over three months by -23.40% and over the past year by -72.37%.

Is OMI a buy, sell or hold?

Owens & Minor has received a consensus analysts rating of 3.33. Therefor, it is recommend to hold OMI.

StrongBuy: 2
Buy: 0
Hold: 2
Sell: 2
StrongSell: 0

What are the forecasts/targets for the OMI price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	5.4	127.6%
Analysts Target Price	5.4	127.6%
ValueRay Target Price	1.2	-50.6%

OMI Fundamental Data Overview February 03, 2026

P/E Forward = 2.6788
P/S = 0.0201
P/B = 1.0748
P/EG = 4.07
Revenue TTM = 6.71b USD
EBIT TTM = -298.6m USD
EBITDA TTM = -48.8m USD
Long Term Debt = 1.84b USD (from longTermDebt, last quarter)
Short Term Debt = 280.0m USD (from shortTermDebt, last quarter)
Debt = 2.20b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.16b USD (from netDebt column, last quarter)
Enterprise Value = 2.38b USD (216.6m + Debt 2.20b - CCE 32.8m)
Interest Coverage Ratio = -2.09 (Ebit TTM -298.6m / Interest Expense TTM 143.0m)
EV/FCF = -6.76x (Enterprise Value 2.38b / FCF TTM -352.2m)
FCF Yield = -14.80% (FCF TTM -352.2m / Enterprise Value 2.38b)
FCF Margin = -5.25% (FCF TTM -352.2m / Revenue TTM 6.71b)
Net Margin = -19.98% (Net Income TTM -1.34b / Revenue TTM 6.71b)
Gross Margin = 26.13% ((Revenue TTM 6.71b - Cost of Revenue TTM 4.95b) / Revenue TTM)
Gross Margin QoQ = 46.21% (prev 47.60%)
Tobins Q-Ratio = 0.59 (Enterprise Value 2.38b / Total Assets 4.04b)
Interest Expense / Debt = 1.32% (Interest Expense 29.0m / Debt 2.20b)
Taxrate = 21.0% (US default 21%)
NOPAT = -235.9m (EBIT -298.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.86 (Total Current Assets 2.13b / Total Current Liabilities 2.47b)
Debt / Equity = -5.11 (negative equity) (Debt 2.20b / totalStockholderEquity, last quarter -429.5m)
Debt / EBITDA = -44.36 (negative EBITDA) (Net Debt 2.16b / EBITDA -48.8m)
Debt / FCF = -6.14 (negative FCF - burning cash) (Net Debt 2.16b / FCF TTM -352.2m)
Total Stockholder Equity = 106.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -29.40% (Net Income -1.34b / Total Assets 4.04b)
RoE = -1260 % (out of range, set to none) (Net Income TTM -1.34b / Total Stockholder Equity 106.4m)
RoCE = -15.38% (EBIT -298.6m / Capital Employed (Equity 106.4m + L.T.Debt 1.84b))
RoIC = -11.37% (negative operating profit) (NOPAT -235.9m / Invested Capital 2.07b)
WACC = 1.74% (E(216.6m)/V(2.41b) * Re(8.80%) + D(2.20b)/V(2.41b) * Rd(1.32%) * (1-Tc(0.21)))
Discount Rate = 8.80% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.31%
Fair Price DCF = unknown (Cash Flow -352.2m)
EPS Correlation: -50.85 | EPS CAGR: -59.98% | SUE: -4.0 | # QB: 0
Revenue Correlation: -59.47 | Revenue CAGR: -28.61% | SUE: -0.01 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.15 | Chg30d=-0.002 | Revisions Net=-2 | Analysts=2
EPS next Year (2026-12-31): EPS=0.97 | Chg30d=+0.001 | Revisions Net=-4 | Growth EPS=-4.2% | Growth Revenue=-17.2%

Additional Sources for OMI Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle